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Correction of a genetic mutation via homologous recombination (HR) is a promising approach 
to actually cure some genetic diseases. To increase HR effi  ciency, DNA damage can be induced 
specifi cally to the target gene using DNA targeting agents such as triple helix forming 
oligonucleotides (TFOs), either alone or fused to DNA damaging agents. In this study, we report 
on sequence-specifi c TFOs conjugated to sequence-specifi c restriction endonucleases as double 
targeted nucleases. TFOs were designed for acid-α-glucosidase (GAA), the gene mutated in Pompe 
disease, and fused to camptothecin or restriction endonucleases. The agents were tested for target 
binding affi  nity by BIAcore, for DNA damage by measuring γH2AX, and for HR induction using 
luciferase reporter plasmids. Co-transfecting TFO-MunI conjugates with a promoter-less reporter 
plasmid and a promoter-containing HR fragment resulted in restoration of luciferase activity to 
up to 24% of the promoter containing control. The data presented here demonstrate that TFO-
restriction endonuclease conjugates are promising candidates for gene correction approaches for 
monogenetic disorders like Pompe disease.
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INTRODUCTION
Gene targeting via homologous recombination (HR) off ers a promising strategy to permanently 
correct genetic disorders. However, spontaneous recombination between an introduced DNA 
and the homologous target occurs at a very low frequency in mammalian cells thereby severely 
hampering therapeutic application1;2. Several approaches can be envisioned to stimulate HR 
frequencies including DNA triplex formation by Triple helix Forming Oligonucleotides (TFOs)3-7. 
TFOs are short synthetic single stranded DNA stretches (12-30 nts) that recognize polypurine: 
polypyrimidine regions in double stranded DNA and bind the purine strand of their target DNA 
in the major groove8;9. To further increase the HR frequency, induction of DNA nickage or double 
strand cleavage specifi cally at a target site can be achieved by fusing DNA damaging agents to 
the TFOs10-14. Towards this end, TFOs have been coupled to chemical DNA damaging agents like 
psoralen14;15, or camptothecin (CPT)10;16. Alternative strategies to induce homologous recombination 
by DNA damage are re-engineered homing endonucleases (so called meganucleases)17 and Zinc 
Finger Proteins  fused to restriction nucleases (ZFN). 
The most advanced approach for introduction of site specifi c DSBs is provided by Zinc Finger 
Nucleases, consisting of a pair of gene-specifi c Zinc Finger Proteins each fused to a FokI monomer18-21. 
The specifi city of the ZFN approach is based on the pair of ZFPs allowing two FokI domains to 
dimerize. Each ZFP consists of modules which each can be engineered to recognize 3 or 4 bp in 
the genome22. An ongoing clinical trial is evaluating ZFNs to disrupt the CCR5 gene in CD4+ human 
T-cells as a potential treatment for HIV/AIDS23.
Gene correction approaches using targeted nucleases are very attractive options for therapeutic 
applications for monogenetic disorders, like Pompe disease. Pompe disease is a severe rare 
autosomal lysosomal storage disorder caused by a mutation in the gene encoding the lysosomal 
enzyme acid-α-glucosidase (GAA). The GAA defi ciency results in glycogen accumulation in the 
lysosomes, eventually causing early death of the patient. The only available therapy is enzyme 
replacement therapy, in which recombinant produced enzyme is supplied intravenously to the 
patient leading to prolongation of life24-26. As GAA is an excreted enzyme, correction of the mutation 
in secreting cells using the gene correction strategy would be very promising to actually cure 
the disease27. In this study, we designed TFOs for GAA genes to be fused to the DNA damaging 
agents camptothecin or to restriction endonucleases and studied induction of DNA damage and 
homologous recombination (HR) events. The approach of TFOs fused to restriction endonucleases 
has been introduced in the early 90’s and demonstrated specifi c cleavage28-30. To our knowledge no 
further research to study HR in living cells has been performed. In this study we set out to evaluate 






Oligonucleotides (TFOs, sequences reported in Table 1) were purchased from Eurogentec 
(Maastricht, the Netherlands). For the BIAcore binding studies target hairpin duplexes labelled with 
biotin at the 5’ end were ordered (Eurogentec) (Table 1). Restriction enzymes used for construction 



















M = 5’-methyl 2’deoxycytidine 
P = 5’- propynyl 2’deoxyuridine
Z = acridine derivative
Underlined sequences are the target sites within the hairpin duplexes
Underlined and bold sequences are TFO binding sites of the linkers
Underlined and italic sequences are Restriction sites of the linkers
Table 1. Sequences of oligonucleotides. 
The table contains the TFO sequences targeting the VEGF, the human GAA or the mouse GAA gene, the 
corresponding target hairpin duplexes used in the BIAcore experiments containing a 13 bp sequence 
(underlined) representing to a region of the human GAA gene, a 20 bp sequence (underlined) representing to a 
region of the mouse GAA gene, and a 20 bp sequence (underlined) representing to a region of the human VEGF 
gene,  and the linkers used for making the reporter plasmids pGL2-hGAA or pGL2-mGAA. 
Construction of TFO-conjugates
Construction of TFO-CPT 
The chemical conjugation of the TFO to CPT has been described in detail elsewhere16. In short, 
the oligonucleotides were purifi ed using quick spin columns and Sephadex G-25 fi ne (Biorad, 
Veenendaal, The Netherlands). Concentrations were determined spectrophotometrically at 
25°C using molar extinction coeffi  cients at 260 nm calculated from a nearest-neighbor model31. 
3’phosphorylated TFO solutions were incubated 4-(dimethylamino)pyridine (5 mg in 25 µl of DMSO, 
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41µmol), dipyridyl disulfi de (6.6 mg in 25µl of DMSO, 30µmol) and triphenylphospine (7.9 mg in 50µl 
of DMSO, 30 µmol) for 15 min at room temperature, CPT was added to the activated oligonucleotide 
and the mixture was kept at RT for 4 h. The conjugate was precipitated by the addition of 2% LiClO4 
in acetone, rinsed with acetone, and purifi ed by reversed-phase HPLC using a linear acetonitrile 
gradient. The oligonucleotide conjugates were characterized by UV spectroscopy and denaturing 
gel electrophoresis32.
Construction of TFO-MunI
Construction of MunIR-H6G4C variant. The plasmid pUHE25-2 MunIR (provided by A. Lagunavicius) 
containing R.MunI gene was used as vector. The stop codon of the MunI gene was replaced to Gly, and 
a BamHI restriction site was created downstream of this Gly by PCR mutagenesis. The pRIZ’-scPvuII-
H6G4C plasmid was used as a template for PCR to obtain DNA fragment encoding for His6Gly4Cys-tag 
at the C-terminus (provided by A. Pingoud33). For amplifi cation of this insert with His6-tag, primers 
were used which introduced BamHI and BglII sites at the ends of this DNA fragment.  After digestion 
with restriction endonucleases BamHI and BglII, the insert was ligated into the pUHE25-2 R.MunI(-
Stop) plasmid through the BamHI site. For protein expression plasmids were transformed into 
Escherichia coli ER2267 (recA1 lacIq lacZM15 zzf::mini-Tn10(Kanr)) strain containing a compatible 
plasmid pMunIM 6.2 (Tcr, Cmr) with the methyltransferase MunIM gene34.
Proteins expression and purifi cation.  ER2267 cells containing the pUHE25-2 plasmids with wt or 
His6-tagged MunI genes (recognition site: CAATTG) were grown in LB medium containing 50 mg/L 
Ampicillin (Ap) and 30 mg/L Chloramphenicol (Cm) at 37C. After 4 hours of induction with 0.2 
mM IPTG cells were harvested by centrifugation. Wt MunI was purifi ed as described previously35. 
Purifi cation of His6-tagged MunI was performed as follows: Cell extract was obtained by sonication. 
The supernatant was applied to a 5 ml Hi-Trap Ni-column (GE healthcare) pre-equilibrated with 
binding buff er (20 mM Na-phosphate (pH 7.4 at 25C), 0.5 M NaCl, 1 mM 2-mercaptoethanol). Then 
the column was washed with binding buff er containing 0.5 mM imidazole and bound protein was 
eluted with a 0.5-500 mM linear gradient of imidazole in 20 mM Na-phosphate (pH 7.4 at 25C), 
0.5 M NaCl, 1 mM 2-mercaptoethanol. Collected protein fractions were dialyzed against 10mM Na-
phosphate (pH 7.4 at 25C), 0.1 M NaCl, 7mM 2-mercaptoethanol and loaded onto 5 ml Hi-Trap 
Heparin column pre-equilibrated with the same buff er. Then the column was washed and bound 
protein was eluted with a 0.1-1.0 M linear gradient of NaCl in 10mM Na-phosphate (pH 7.4 at 25C), 
7mM 2-mercaptoethanol.
Wt and His6-tagged MunI were stored at -20C in storage buff er (10 mM Tris-HCl (pH 7.4 at 25C), 
100 mM KCl, 1 mM EDTA, 1 mM DTT, 50 % glycerol). The concentrations of proteins were determined 
spectrophotometrically at 280 nm using the extinction coeffi  cient of 45720 M-1cm-1. Heterodimeric 
variant of MunI containing a single His-tail was generated by incubating equimolar amounts and 
coupled to the oligonucleotide according to the method described previously33.
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MunI-TFO purifi cation. To separate MunI-TFO conjugates from unreacted MunI MonoQ 5/50 GL 
column (supplier) was used. The reaction mixture was loaded on the column equilibrated with buff er 
20 mM Tris (pH 7.4 at 25C), 0.1M NaCl, 7mM 2-mercaptoethanol. Bound protein-TFO crosslink was 
eluted with a 0.1-1.0 M linear gradient of NaCl. MunI-TFO conjugates were stored at -20C in storage 
buff er (10 mM Tris-HCl (pH 7.4 at 25C), 100 mM KCl, 1 mM EDTA, 50 % glycerol) until further use.
Surface plasmon resonance biosensor (BIAcore) 
TFO binding experiments were performed on a BIAcore 3000 instrument (GE Healthcare, Zeist, the 
Netherlands) at a temperature of 37°C. SA sensor chips (GE Healthcare) were used, consisting of 
four analysis fl ow lanes coated with streptavidin. The chip surface was conditioned by 3 times 1 
min injections of 1M NaCl, 50mM NaOH, at a fl ow rate of 20 µl/min. Biotinylated target hairpins 
(Eurogentec, see Table 1) were bound to the appropriate fl ow cell on the SA sensor chip by injecting 40 
µl solution of 200 nM target duplex at fl ow rate 10 µl/min, resulting in 1000-2000 RUs of immobilized 
target DNA. Binding experiments were carried out in MES binding buff er (50 mM MES-HCl, pH 5.5-
6.5, 5 mM MgCl2, 0.005% polyoxyethylenesorbitan (P20, GE Healthcare)), at the indicated pH. TFO 
solutions (Table 1) were prepared by adding 2 µl of 100 µM TFO solution to 48 µl binding buff er and 
35 µl was injected over the sensorchip surface at a 20 µl/min fl ow rate. Dissociation was monitored 
for 240 seconds after the end of the injection. The surface of the chip was regenerated  with HBS-EP 
(20 mM HEPES, pH 7.4, 150 mM NaCl, 5 mM EDTA, 0.005% P20; contact time 30s), followed by 10 mM 
Na-borate, pH 8.5, 1 M NaCl (contact time 60 s). 
Affi  nity measurements were performed by a series of 250 µl injections of TFO in the concentration 
range 16-4100 nM at 37°C at a fl ow rate of 10 µl/min in MES binding buff er pH 6.5, followed by a 
60 s regeneration with Na-borate, pH 8.5, 1 M NaCl. The sensorgrams were analysed with the 1:1 
Langmuir model using BIAevaluation 4.1 (GE Healthcare), resulting in values for the association and 
dissociation rate constants from which the dissociation constant KD was calculated.
Cell culture and transfections 
The human ovarian carcinoma cell lines A2780 was obtained from the ATCC (Manassas, VA, USA) and 
cultured in RPMI 1640 (BioWhittaker, Walkersville, USA) supplemented with 10% FBS (BioWhittaker), 
L-glutamine (200mM), Na-Pyruvate (100mM), β-mercaptoethanol (0.05M), gentamycine (10 mg/mL) 
at 37C under humidifi ed conditions. Mouse 3T3 fi broblasts (obtained from ATCC) were cultured in 
Dulbecco's modifi ed Eagle's medium (DMEM) supplemented with 50 μg/ml gentamycine sulfate, 2 
mM L-glutamine, 10% FBS.
Transfection experiments were carried out using SAINT:MIX (SM) as transfection agent (Synvolux 
Therapeutics B.V., Groningen, the Netherlands). A2780 cells were seeded (4 x 104 cells in 96 well 
plate) and the next day, at a confl uency of 50-80%, transfected with a total amount of 300 ng DNA 
for 96 wells with or without 0.25µM TFO-MunI or an irrelevant TFO-BseI conjugate unless stated 
otherwise. For γH2AX FACS experiments, A2780 cells were seeded at 1.8 x 105 cells (or 7 x 104 cells 
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for 3T3) in 24 well plates and transfected with 2µM TFO.
TFO binding to DNA in living cells
Induction of DNA damage as measured by phosphorylated H2AX using FACS was described 
previously by us36 and others for TFO induced damage37. In brief, cells were seeded in 24 well 
plates and 2 µM of TFO-CPT or TFO alone was transfected using SM. At indicated time points after 
transfection, cells were harvested and washed with PBS. Cells were fi xed in 4% Formaldehyde (Merck, 
Darmstadt, Germany) in PBS for 10 minutes at 37°C. After addition of 1 ml PBS and chilling on ice for 
1 min, cells were washed and permeabilized in 90% methanol in PBS for 30 minutes on ice. Staining 
of phosphorylated H2AX (γH2AX) was performed as follows: permeabilized cells were washed by 
addition of 2 ml of incubation buff er (0.5% BSA in PBS). Cells were resuspended in 90 µl incubation 
buff er followed by addition of 10µl of conjugated antibody (rabbit mAb phospho histone H.2AX 
(ser139, 20E3) alexa fl uor 488 conjugate)  (Bioké, Leiden, The Netherlands) and were incubated for 
30 minutes in the dark at RT. Cells were washed again with incubation buff er, resuspended in 200µl 
PBS and analyzed for phosphorylated H2AX staining using a Calibur fl ow cytometer (BD Biosciences, 
San Jose, CA). 
Construction of reporter plasmids (Figure 1)
To test TFO conjugates for induction of HR, several reporter plasmids were designed. We fi rst 
constructed reporter plasmids containing diff erent TFO binding sites and restriction sites upstream 
of the GFP reporter gene. As GFP was too stable to study induction of double strand breaks, we 
focused on designing reporter plasmids containing the diff erent TFO binding sites and the restriction 
sites upstream of the luciferase gene of the basic vector pGL2 (Promega, Leiden, the Netherlands) 
with and without the CMV promoter. For construction of the reporter plasmids for the human GAA 
gene, pGL2 was digested with HindIII, treated with Klenow Fragment to fi ll in the overhang followed 
by dephosphorylation according to the manufactures protocol (Fermentas, St. Leon-Rot, Germany). 
The linker hGAA oligonucleotides (see Table 1) were annealed, treated with Klenow Fragment to fi ll 
in the overhang, phosphorylated and inserted into the digested pGL2 vector. The resulting linker 
plasmid, pGL2-hGAA (Figure 1), contained the Triple Helix binding Site (TFS) (underlined and bold) 
and the restriction sites (underlined and italic). The CMV promotor was obtained from pcDNA3 
(Invitrogen) after digestion with BamHI and BglII and subcloned into the dephosphorylated BglII 
site of pGL2-hGAA, resulting in a pGL2-CMV-hGAA reporter. 
To obtain reporter plasmids for the mouse GAA gene, the basic vector pGL2 was digested with 
BglII and HindIII. The linker mGAA oligonucleotide, also containing the UpI Zinc Finger Binding 
site38 (see Table 1), was annealed, phosphorylated and inserted into the digested pGL2 vector. 
This reporter plasmid was called pGL2-mGAA. To obtain pGL2-CMV-mGAA, the CMV promotor 
was excised from pcDNA3 using BamHI and MluI and subcloned in pGL2-mGAA. All plasmids were 
verifi ed by sequencing.
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Homologous recombination studies on plasmid level 
Predigested plasmids. First, 20 µg of plasmids were pretreated with PvuII, followed by AgeI in 
Buff er Green and Buff er Orange, respectively for 1 h each followed by purifi cation of the digested 
plasmid via the Qiagen gel purifi cation kit. Quantifi cation of the plasmids was done by nanodrop 
measurements. The homologous recombination fragment was obtained from pGL2-CMV by 
Figure 1. Schematic representation of reporter plasmids and homologous recombination fragment.
A. Construction of reporter plasmids containing the Triplex Forming binding sites for the human GAA gene. B. 
Construction of reporter plasmids containing Triplex Forming binding sites for the mouse GAA gene. Insertion of 
a DraIII - EcoRI fragment of pGL2-CMV and pGL2-mGAA or pGL2-hGAA will result in the introduction of the CMV 
promoter. C. The HR fragment was obtained by digestion of the pGL2-CMV plasmid with DraIII and EcoRI. This 
fragment contained 588 bp of homology upstream of the none CMV-containing reporter plasmid and 596 bp of 
homology in the luciferase gene downstream of the restriction sites.
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digestion with DraIII and EcoRI, and contains 588 bp of homology with the promoter-less reporter 
plasmids upstream and 596 bp of homology in the luciferase gene downstream of the restriction 
sites (Figure 1C). 31.5 ng of predigested plasmid was co-transfected with a 3.3-fold molar excess 
of homologous recombination fragment in a 96 well plate. In the experiments, irrelevant plasmid 
pFASTbac was added to fi ll up to a total of 63 ng of DNA in every transfection. 48 h after the 
transfection experiments, cells were washed with PBS and 100μl 1x passive lysis buff er (Promega 
luciferase assay system, Promega) was added to each well. The plate was incubated for 15 minutes 
at room temperature. Next, 30 µl of lysate was added to 50µl LAR II in a white 96-well plate. Relative 
luciferase intensity was measured on a LuminoSkan ascent (Thermo scientifi c, Waltham, MA, US). 
Pretreatment of plasmids by TFO-conjugates. 
25 nM of plasmids were pretreated with or without 0.09µM TFO-MunI conjugate in a buff er containing 
50 mM TrisHCl pH7.2 at 37°C, 50 mM KCl, 10 mM MgCl2, 0,5 mM DTT. Pretreatment with TFO-MunI 
of the plasmids took place during 24 h directly prior to transfection. Next, pretreated plasmids were 
co-transfected with a 3.3-fold molar excess of homologous recombination fragment or an irrelevant 
fragment. In all experiments, irrelevant plasmid pFASTbac was added to fi ll up to a total of 300 ng of 
DNA in every transfection. The homologous recombination fragment was obtained from pGL2-CMV 
by digestion with DraIII and EcoRI, and contains 588 bp of homology with the none CMV-containing 
reporter plasmids upstream and 596 bp of homology in the luciferase gene downstream of the 
restriction sites (Figure 1C). 48 h after the transfection experiments, luciferase assay was performed 
as described above. 
Co-transfection TFO-MunI, reporter plasmid and donor fragment. 
103.7 ng of reporter plasmid was co-transfected with 0.25µM TFO-MunI and with a 3.3-fold molar 
excess of homologous recombination fragment. Again, irrelevant plasmid pFASTbac was added to 
fi ll up to a total of 300 ng of DNA in every transfection. 48 h after transfection, luciferase assay was 
performed as described above. 
Statistics  
Statistical comparisons were performed using the one-tailed paired t-test. Statistical signifi cance 
was indicated by P < 0.05 (*), and P < 0.01 (**).
RESULTS 
Kinetics of triple helix formation
Surface plasmon resonance biosensor was used to investigate the binding, kinetics and selectivity 
of mTFO and hTFO targeting the murine and the human GAA gene (mGAA and hGAA), respectively. 
Two TFOs targeting the VEGF gene (TFO-GU and TFO-TM) were included as positive controls39. Each 
of the three target hairpin duplexes (Table 1) were immobilized at the surface of a diff erent fl ow 
cell on a SA sensor chip leaving one fl ow cell empty. The diff erent TFO solutions were injected to all 
four lanes to analyze the binding of the TFO to the hairpin duplexes (Figure 2). The positive controls 
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TFO-GU and TFO-TM both induced a specifi c resonance signal (80 and 30 Resonance Units (RU)), 
respectively, at pH 6.5) when injected over the VEGF1 target hairpin duplex while no signal was 
obtained for the hGAA and mGAA targets (Fig 2A and B). 
In the case of the GAA target, the hTFO was able to bind its target duplex with great affi  nity 
at pH 6.5, as a strong resonance signal (110 RU) was observed for the fl ow cell with immobilized 
human GAA hairpin duplex (Figure 2C). No signal was observed for hTFO on the other two targets 
(VEGF and murine GAA), indicating highly selective binding of this TFO. At 25ºC, several injections 
of Na-borate were needed for full regeneration of the hGAA TFO bound to hGAA. Interestingly, no 
binding of hTFO to its target duplex was observed in HBS-EP (data not shown). Furthermore, affi  nity 
measurements of hTFO revealed a binding affi  nity of 19 nM.
The mTFO only induced a resonance signal when allowed to bind to the murine GAA target 
duplex at pH5.4 and 6.0 (90 and 40 RU, respectively), but the cross binding to VEGF target indicate 
low selectivity (70 and 30 RU, respectively) (data not shown). Binding to murine GAA target duplex 
was very much reduced at pH 6.5 (15 RU) (Figure 2D). 
TFO binding to DNA in living cells 
After establishing binding of hTFO on naked target DNA, we investigated whether hTFO or hTFO fused 
to CPT could bind DNA into the nuclei of cells by detecting DNA damage through phosphorylated 
Figure 2. BIAcore analysis to study the specifi city of TFO binding. 
Sensorgrams showing injection of 2 µM TFO over surfaces containing immobilized hGAA (green line), mGAA 
(blue line) and VEGF (red line) target hairpin duplexes for A. TFO-GU (VEGF), B. TFO-TM (VEGF), C. hTFO targeting 
hGAA, D. mTFO targeting mGAA. (see table 1 for sequences). Experiments are performed at pH 6.5 and 37°C.
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histone H2AX measurements. Upon induction of DNA damage, the histone H2AX becomes rapidly 
phosphorylated and is recruited to the site of DNA damage. Cells were analyzed for phosphorylated 
H2AX (γH2AX) using FACS analysis, 3 and 18 hours after transfection with human TFO constructs 
(Figure 3). The data were analyzed using WinList software. As untreated cells are known to contain 
background levels of γH2AX, the cut off  for γH2AX for each independent experiment in human 
A2780 cells was set at the MFI were the SM treated cells and the scPvuII treated cells cross each 
other (see arrow in Figure 3 C and D). Treatment with hTFO-3’CPT resulted in a detectable increase 
in phosphorylation of H2AX, 3 hours after transfection: 48.6 ± 5.2 % of the cells were positive for 
phosphorylated H2AX compared to 3.9 ± 1.03 % for SM treated cells (P = 0.038) (Figure 3A and C). 
The percentage of positive cells decreased  to 6.7 ± 1.1 % 18 h after hTFO-3’CPT treatment which was 
still signifi cantly higher compared to the 3.8 ± 1.01 % positive cells observed for SM treated cells 
(P = 0.03) (Figure 3B and D). For the treatment with hTFO only, no statistically signifi cant increase 
Figure 3 Induction of DNA damage by TFO-CPT or TFO agents after transfection. 
A2780 cells were treated with 2µM hTFO, TFO-CPT conjugates or 1µg of scPvuII. After 3 (A and C) and 18 h (B 
and D), cells were collected and stained for phosphorylated H2AX (γH2AX). FACS analysis was performed to 
analyze γH2AX. Transfections were performed in duplo for three independent experiment. Data are represented 
as means of the means ± SEM (Figure 3 A and B). Statistical comparison was performed between SM treated 
cells and cells treated with TFO only, hTFO-3’CPT or scPvuII. Figure 3 C and D show representative histograms 
as an example. Vertical dotted line represents treshold for background γH2AX levels. Graphs were made using 
WinMDI software. 
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in phosphorylation status of H2AX could be observed 3 hours after transfection (6.8 ± 3.3 %), but 
increased to 9.1 ± 0.38 % (P = 0.03) 18 h after transfection (compared to 3.94 ± 1 % and 3.8 ± 1 % of 
SM treated cells respectively). Direct delivery of the restriction enzyme PvuII resulted in pronounced 
H2AX staining, 52.2 ± 8.7 % of the cells were positive after 18 h (P = 0.018) (Figure 3 B and D). For the 
murine 3T3 cells, no statistically signifi cant increase in γH2AX above background could be observed 
for mTFO only or for mTFO-CPT. Treatment of the cells with scPvuII, resulted in 32.6 ± 13.2 % (P = 
0.02) and 44.5 ± 23.6 % (P < 0.01) of positive cells for γH2AX  after 3 h and 18 h respectively. 
Homologous recombination: pre-digested reporter plasmids
In order to develop a read out system for induction of HR on the GAA gene by GAA targeting agents, 
pGL2 luciferase plasmids were constructed with and without a CMV promoter and containing 
TFO binding sites and enzyme restriction site upstream of luciferase (see Figure 1). As a proof of 
principle, predigested gel purifi ed pGL2-hGAA plasmids (with and without the CMV promoter) 
were transfected with irrelevant DNA or with the homologous recombination fragment (Figure 4). 
Figure 4. Reconstitution of luciferase reporter gene by homologous recombination.
Reporter plasmid pGL2 without CMV promoter was digested in the tube (RE), gel purifi ed and transfected with 
either 3.3 fold molar excess of the homologous recombination fragment (HRF) or with irrelevant DNA. After 
48 hours luciferase activity was determined. The luciferase expression of pGL2-CMV-hGAA was set at 100% for 
each independent experiment. A. One experiment in triplo (mean ± SD) is shown as a representative of two 
independent transfection experiments. B. Similar experiment as in (A) have been performed with pGL2-mGAA. 
Transfections were performed in triplo for three independent experiments. Data are represented as means of 
the means ± SEM.
Luciferase expression of the pretreated, undigested gel purifi ed pGL2-CMV-mGAA (control) was 
set at 100% for each independent experiment. As expected, transfection of the digested pGL2-
hGAA or of the CMV-containing homologous recombination fragment alone did not result in 
detectable luciferase activity. Pre-digestion of pGL2-CMV-hGAA reduced luciferase activity to 55 
± 10.4 % of the luciferase activity of the uncut, gel purifi ed plasmid (Figure 4A) (or 79 ± 19.9 % for 
the second independent experiment performed in triplo). Co-transfection of the digested pGL2-
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% compared to pGL2-CMV-hGAA plasmid (P < 0.01) (Figure 4A) or 188 ± 38.9 % (P = 0.02) for the 
second independent experiment performed in triplo). Interestingly, co-transfection of the digested 
pGL2-hGAA with the homologous recombination fragment restored luciferase activity to 88 ± 
23.2% compared to the undigested pGL2-CMV-hGAA plasmid (P = 0.0319)  (Figure 4B).
Pretreatment with targeted nuclease does not increase homologous recombination frequency
To study the eff ect of a double targeted TFO-nuclease , we digested the reporter plasmid 
by pretreatment with the TFO-MunI conjugate followed by transfection with or without the 
homologous recombination fragment (Figure 5). Luciferase expression of the pretreated pGL2-CMV-
mGAA without TFO-MunI (control) was set at 100% for each of the three independent experiments. 
In the presence of HR fragment, the percentage of luciferase expression was unchanged (Figure 5A). 
Pretreatment of pGL2-CMV-mGAA with TFO-MunI resulted in a reduction of luciferase activity to 
background levels. Co-transfecting the HR fragment with the digested pGL2-CMV-mGAA restored 
luciferase gene activity to 2.2 ± 0.26 % (P < 0.01) (Figure 5A). 
Undigested pGL2-mGAA, when cotransfected with HRF, resulted in a reconstitution of  3.7 
± 0.73 % (Figure 5B) and 5.6 ± 3.1 % (data not shown) compared to pGL2-CMV-mGAA for two 
independent experiments performed in triplo.Pretreatment of pGL2-mGAA by TFO-MunI could not 
further increase the frequency of homologous recombination (3.3 ± 0.31% and 4.45 ± 1.1 % for the 
two independent experiment performed in triplo) as compared to the spontaneous homologous 
recombination observed for undigested pGL2-mGAA. 
Figure 5. Pretreatments with TFO-nuclease conjugates does not increase induce homologous 
recombination. Plasmids were pretreated with or without 0.09µM TFO-conjugates and transfected with or 
without homologous recombination fragments (HRF) into cells. Total amount of DNA was 300 ng in each well. 
After 48 hours, luciferase activity was determined. The luciferase expression of pGL2-CMV-mGAA was set at 100% 
for each independent experiment. A. Transfections were performed in triplo for three independent experiment. 
Data are represented as mean of the means ± SEM. B. One experiment in triplo is shown as a representative of 



















































































































































To exclude unaddressed cleavage, we digested the plasmids with TFO-MunI, with and without 
Mg2+, and analyzed the samples on agarose gel. In the presence of Mg2+, the TFO-MunI conjugate 
hydrolysis all restriction recognition sites present in the plasmid. Without Mg2+ no digestion of the 
plasmid was observed at all (Figure 6A). Co-transfection experiments of the pretreated reporter 
plasmid, pGL2-mGAA with the TFO-nuclease conjugate (without Mg2+ in the incubation buff er) 
with the HR fragment revealed no increase in HR events (6.2 ± 3.6%) compared to spontaneous HR 
(8.7 ± 5) (Figure 6B).
Figure 6. Infl uence of Mg2+ on induction of DNA damage and HR induction by TFO-nuclease conjugates. A. 
Plasmids were pretreated with 0.09µM TFO-conjugates (with or without Mg2+) and samples were analyzed on a 
agarose gel. 1. DNA ladder mix; 2. pGL2-mGAA; 3. pGl2-mGAA + TFO-MunI; 4; pGl2-mGAA + TFO-MunI + Mg2+; 5 
pGL2-CMV-mGAA; 6. pGl2-CMV-mGAA + TFO-MunI; 4; pGl2-CMV-mGAA + TFO-MunI + Mg2+. B. Co-transfection 
of pretreated plasmid with 0.09µM TFO-conjugate (without Mg2+) with or without homologous recombination 
fragments (HRF) was performed in A2780 cells. Total amount of DNA was 300 ng in each well. After 48 hours, 
luciferase activity was determined. The luciferase expression of pGL2-CMV-mGAA was set at 100%. Transfections 
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Induction of homologous recombination after co-transfection of the reporter plasmid, TFO-
MunI and donor fragment
To investigate the potency of the TFO conjugate to bind and cut its target within the reporter plasmid, 
we co-transfected TFO-MunI and the reporter plasmids with irrelevant DNA or with HR fragment in a 
cellular context. Co-transfection of pGL2-CMV-mGAA with TFO-MunI reduced luciferase expression 
to approximately 31.7 ± 4.4 % (Figure 7) and 6.6 ± 3.6 % (data not shown) for two independent 
experiments performed in triplo (luciferase expression of pGL2-CMV-mGAA was at 100% for 
each independent experiment). For pGL2-mGAA, co-transfection of TFO-MunI with HR fragment 
resulted in 24.6 ± 7.3 % (Figure 7) and 8.2 ± 4.8 % (data not shown) of recombination. To rule out the 
possibility that the observed decrease in luciferase expression after co-transfection of the reporter 
plasmid and TFO-MunI is due to decreased delivery effi  ciency, co-transfection experiments were 
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Figure 7 Co-transfection of reporter plasmids with TFO-nuclease with 
HR fragment induces homologous recombination. A2780 cells were 
cotransfected with reporter plasmids, 0.25 µM TFO-conjugate and with or 
without HR fragment. Total amount of DNA was 300 ng in each well. After 48 
hours, luciferase activity was determined. The luciferase expression of pGL2-
CMV-mGAA was set at 100% for each independent experiment. Transfections 
were performed in triplo for two independent experiments. One experiment 













































































performed using an irrelevant TFO-Bse conjugate as control. No signifi cant diff erence was observed 
in luciferase activity of pGL2-CMV-mGAA with or without inclusion of TFO-BseI (data not shown). 
Therefore, the action of TFO-MunI is held responsible for the decrease in luciferase expression as 
shown in Figure 7.
DISCUSSION
Gene correction via homologous recombination (HR) provides a promising approach for 
monogenetic diseases. Because spontaneous recombination occurs at a low frequency (1 event per 
105 to 107 treated cells40), several research groups focused on unconjugated TFOs to increase HR 
and demonstrated HR frequencies up to 0.4% 4-6;41. Induction of double strand breaks (DSB) near 
the site of interest has been shown to further increase the HR frequency21;42;43. For monogenetic 
disorders like Pompe disease, such targeted gene correction strategies could be attractive 
alternatives to actually cure the disease. Lu et al. previously demonstrated that correction of a point-
mutation (C1935  A) found in Pompe patients is feasible using single stranded oligonucleotides. 
This oligonucleotide was 35 nts long and recognized a contiguous stretch of DNA residues entirely 
homologous to the target sequence containing one mismatch to correct this point mutation. 
Transfection of the oligonucleotide in Pompe derived fi broblasts leads to correction of enzymatic 
activities up to 4% of GAA activity of healthy controls27. In the present study, we set out to further 
improve on the specifi city and/or effi  ciency of gene correction by developing targeted nucleases for 
improved induction of HR in vitro. The double targeted nucleases used in our study were composed 
of DNA binding domains (Triple helix Forming Oligonucleotides (TFOs)) fused to sequence-specifi c 
restriction endonucleases. 
Of the diff erent TFOs used in our study, TFO-TM and TFO-GU were effi  cient in binding their 
targets and TFO-GU seems to be more specifi c compared to TFO-TM confi rming previous results39. 
The TFO targeting the human GAA gene (hTFO) was very effi  cient in binding its target duplex at pH 
6.5. No binding of hTFO to its target duplex was observed in buff er HBS-EP, whereas already formed 
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complex could not be regenerated by injection with HBS-EP. Apparently, the surface between 
the two interacting DNA’s is rather tight and more extreme conditions are needed to break this 
interaction in comparison to any of the other interactions. At low pH, some cross-binding at the 
VEGF-target was detected, which might be explained because of a 6 bp sequence overlap (Table 1). 
In this study, we observed a binding affi  nity in the range of 19 nM for the hGAA-TFO, which is 
considered to be very good44;45.
The TFO targeting the mouse GAA gene (mTFO) showed binding to its target sequence only at 
low pH but also showed binding at the VEGF target probably because of the presence of many 
Cs that are positively charged at low pH39. At pH 6.5, the binding of mTFO to its target was almost 
lost, which could be explained by the fact that the TFO contained two inversions in the recognition 
sequence thereby reducing the binding affi  nity44. The possibility to design a TFO on a polypurine-
polypyrimidine stretch containing inversions has been reported previously46, future studies 
will focus on TFOs to direct (mutated) MunI conjugates to its site in the mGAA gene. We did not 
observe increased phosphorylation of H2AX by mTFO above background in the mouse 3T3 cell 
line (performed for two independent experiments in duplo) which could be explained by the fact 
that the mTFO constructs possessed no affi  nity for its target as shown by the BIAcore studies. This 
implicates that camptothecin has no off -target eff ect when conjugated to a TFO.
Nuclear localization of a 125I-TFO and the DNA damaging agent camptothecin (CPT) has 
previously been confi rmed by analyzing the DNA damage response protein γH2AX by FACS analysis 
and western blot respectively37;47. In this study, we investigated the nuclear localization of a TFO 
fused to CPT. The levels of γH2AX observed in the human line A2780 for hTFO-3’CPT in A2780 were 
lower compared to the positive control scPvuII which would indicate specifi city. For the hTFO, the 
γH2AX signal became more apparent 18h after delivery. 
To avoid chromatin complexicity, reporter plasmids were used as a model system to demonstrate 
proof-of-principle for induction of HR by the double targeted nucleases. As donor fragments, 
researchers have been using ss donor fragments6;41 or donor plasmids48;49 to study induction 
HR. Majumdar et al. demonstrated that TFO-psoralen in combination with a ds donor fragment 
containing 1.5 kb of homology arms, induced gene knock-in at frequencies 2-3 fold greater over 
donor alone14, indicating that the use of ds donor fragments are also suitable candidates for HR 
studies. Here, we used a ds donor fragment containing 588 bp and 596 bp of homology arms. First, 
we demonstrated proof of principle of our reporter assay by co-transfecting a digested, gel purifi ed 
fragment and HRF. 
TFO-MunI was used to further investigate induction of HR on plasmid level. We observed 
spontaneous recombination for untreated promoter-less plasmid in the presence of the ds donor 
promoter-containing fragment. Pretreatment of the plasmid with TFO-MunI could not further 
increase this spontaneous HR. As we observed lowering in luciferase expression in cells transfected 
with pretreated pGL2-CMV-mGAA and TFO-MunI, we assume that MunI was able to digest the 
plasmid. Further investigation revealed that pretreatment of the plasmid with TFO-MunI leads to 
109
Double targeting restriction endonucleases
7
digestion of the plasmid not only near the TFO sequence but also at other restriction sites in the 
plasmid including the luciferase gene. In the pre-incubation buff er, magnesium ions were present 
which are necessary for the restriction enzymes to bind the DNA and to cleave to the DNA50, and 
we showed that Mg2+ is responsible for complete digestion of the plasmid. However, depleting 
magnesium from the buff er did not result in higher levels of HR induction. Other possibilities 
such as delivery, and binding of the mTFO could be infl uencing the HR results as well. Co-delivery 
experiments with an irrelevant TFO conjugate demonstrated that the TFO conjugate is not 
infl uencing the delivery of reporter plasmids. Therefore, the observed HR frequencies could not be 
ascribed to delivery issues. The mTFO binding to its target could be a more reasonable explanation, 
as BIAcore analysis demonstrated a low binding affi  nity. This could lead to complete digestion of the 
plasmid in stead of site-specifi c cleavage thereby hampering HR induction.
To evaluate the potency of TFO-MunI in the cellular context, direct co-transfection experiments 
were performed with reporter plasmids and TFO-MunI. pGL2-CMV-mGAA co-transfected with 
TFO-MunI resulted in a decrease in luciferase expression, which would indicate binding of the TFO. 
However, an irrelevant TFO fused to MunI should be used as well in order to exclude the possibility 
of unaddressed cleavage of the plasmid by MunI which could also lead to lowered luciferase 
expression. In this study, we showed induction of HR after co-transfection of pGL2-mGAA with 
TFO-MunI and the promotor-containing HR fragment. These results, however, do not rule out the 
possibility of HR induction by the TFO itself or by digestion of MunI at other sites in the plasmid. 
Therefore, TFO alone and MunI fused to an irrelevant TFO should be included in future experiments 
in order to proof the ability of TFO-MunI to induce specifi c and increased induction of HR.
In conclusion, the work reported here demonstrated that the constructed reporter plasmids 
are suitable model systems to study targeted nucleases for gene correction approaches. More 
importantly, we demonstrated proof of concept of targeted nucleases and their ability to induce 
homologous recombination and that delivery is not the limiting factor. Improving the properties 
of restriction endonucleases, such as engineering a caged or a photoswitchable version51;52, could 
further increase the specifi city of the targeted nucleases. In this study, the hTFO demonstrated a high 
affi  nity for its target site and is therefore a very suitable candidate for engineering TFO-nucleases. 
In the hGAA gene, a PvuII restriction is situated near the TFO targeting site and thus PvuII could 
be used as restriction endonuclease. Previously, Eisenschmidt et al. demonstrated the promise of 
such a TFO-scPvuII conjugate as it induced specifi c cleavage on plasmid level33. We propose that the 
approach of a DNA Binding Domain (TFO) fused to a sequence-specifi c restriction endonuclease 
exhibits an increased specifi city and off ers a very promising future therapeutic approach for 
monogenetic diseases like Pompe disease.
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